LDS/Medical Tests/Propoxyphene, Urine

Propoxyphene, Urine

Propoxyphene is a mild opioid agonist that is structurally similar to methadone. Propoxyphene was removed from the US market in 2010 at the request of the FDA due to the cardiac toxicity associated with therapeutic doses. The FDA concluded that the safety risks outweigh the benefits of the drug. The typical route of administration was oral. Propoxyphene is rapidly metabolized to norpropoxyphene. Norpropoxyphene is further N-demethylated to dinorpropoxyphene, which is further metabolized to a cyclic dinorpropoxyphene. Several conjugates may also be formed. The half-life of propoxyphene is 8-24 hours.

Approximately 75% of a single oral dose is eliminated in the urine over 7 days. Actual elimination depends on factors such as drug formulation dose, dose frequency, clinical status and pharmacokinetics of the individual patient.  

Common side effects: sedation, nausea, vomiting, dizziness, headache, miosis, blurred vision, constipation, urinary retention, and pruritis. Cardiac toxicity observed at therapeutic doses has been manifested by arrhythmias, prolonged PR interval, and widened QRS complex, in addition to hypotension, pulmonary edema, and circulatory collapse. Can be addictive and can lead to withdrawal symptoms in newborns of propoxyphene-using mothers. Overdose effects include cardiac arrest, coma, convulsions, circulatory and respiratory collapse, and possible death.  

Propoxyphene and metabolites can be detected in urine by a variety of analytical methods (see below), although availability of testing has declined since the drug was removed from the US market; both qualitative and quantitative tests may be available.

  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A positive result from this test indicates only the presence of Propoxyphene and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, TLC, or GC/MS.

Therapeutic Level: 10-100 ng/mL
Toxic level: >200 ng/mL

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, or whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.

 

Enzyme Immunoassay for screening. 

Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), Thin Layer Chromatography (TLC), or Immunoassay (IA). Targeted assays can distinguish between propoxyphene and metabolites, although poor stability may contribute to false negative or contradictory results. Many laboratories include a pre-analytical hydrolysis reaction to liberate the glucuronide conjugates, which may improve detection.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 4-7 days
  • Frozen: 30 days
Any Positive test result should be confirmed by either GC, TLC, or GC/MS. Additional supportive testing may include Liver profile, Kidney profile, Comprehensive Metabolic Panel, CBC, Urine Drug Screen.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • JAMA. 1975 Sep 22;233(12):1257. [PMID: 1174181]
  • J Addict Dis. 2010 Oct;29(4):436-48. [PMID: 20924879]
  • Ann Clin Biochem. 1997 Sep;34 (Pt 5):460-510. [PMID: 9293303]
  • Urine Testing for Drug Abuse. National Institute on Drug Abuse (NIDA) Research Monograph. 73, 1986.
  • Howanitz JH, Howanitz PJ and Henry JB. Therapeutic Drug Monitoring and Toxicology in Clinical Diagnosis and Management by Laboratory Method. Henry JB (Ed). Philadelphia, WB Saunders Company Vol 1. 477 (1979).